Pelicon Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 09-12-2024
- Paid Up Capital ₹ 2.40 M
as on 09-12-2024
- Company Age 44 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 4.64 Cr
as on 09-12-2024
- Revenue %
(FY 2022)
- Profit 2772.51%
(FY 2022)
- Ebitda -14680.90%
(FY 2022)
- Net Worth 3847.32%
(FY 2022)
- Total Assets 272.95%
(FY 2022)
About Pelicon Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.40 M.
The company has closed loans amounting to ₹4.64 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ratan Sarawagi and Suman Sarawagi serve as directors at the Company.
- CIN/LLPIN
U24231WB1980PTC032999
- Company No.
032999
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Sep 1980
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
24 Parganas, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Pelicon Pharmaceutical?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ratan Sarawagi  | Director | 16-Nov-2017 | Current |
| Suman Sarawagi | Director | 01-Dec-2018 | Current |
Financial Performance of Pelicon Pharmaceutical.
Pelicon Pharmaceutical Pvt Ltd, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 2772.51% increase in profit. The company's net worth Soared by an impressive increase of 3847.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pelicon Pharmaceutical?
Unlock access to Pelicon Pharmaceutical's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Varun Polyplast India Private LimitedActive 15 years 14 daysRatan Sarawagi and Suman Sarawagi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 31 Oct 2005 | ₹2.88 Cr | Satisfied |
Bank Of Baroda Creation Date: 10 Sep 2003 | ₹1.76 Cr | Satisfied |
How Many Employees Work at Pelicon Pharmaceutical?
Unlock and access historical data on people associated with Pelicon Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pelicon Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pelicon Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
